SVRA
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Savara received European and Australian patents for the liquid formulation of MOLBREEVI, extending protection until March 2041Jul 31, 2026
- UK regulator accepted marketing application for MOLBREEVI to treat autoimmune PAPApr 7, 2026
- Savara announces European Patent Office intends to grant patent for MOLBREEVI* liquid formulationDec 11, 2025
- Savara and PARI granted European patent covering drug-device combination of MOLBREEVI* delivered via proprietary eFlow® nebulizer systemDec 2, 2025
- Savara presents new data from Phase 3 IMPALA-2 clinical trial of Molgramostim inhalation solution in patients with autoimmune pulmonary alveolar proteinosis (aPAP) at ERS Congress 2025Sep 29, 2025